Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Cysteinyl leukotrienes (CysLTs) are potent lipid mediators widely known for their actions in asthma and in allergic rhinitis. Accumulating data highlights their involvement in a broader range of inflammation-associated diseases such as cancer, atopic dermatitis, rheumatoid arthritis, and cardiovascular diseases. The reported elevated levels of CysLTs in acute and chronic brain lesions, the association between the genetic polymorphisms in the LTs biosynthesis pathways and the risk of cerebral pathological events, and the evidence from animal models link also CysLTs and brain diseases. This review will give an overview of how far research has gone into the evaluation of the role of CysLTs in the most prevalent neurodegenerative disorders (ischemia, Alzheimer's and Parkinson's diseases, multiple sclerosis/experimental autoimmune encephalomyelitis, and epilepsy) in order to understand the underlying mechanism by which they might be central in the disease progression.

Original languageEnglish
Article number3454212
JournalMediators of Inflammation
Volume2017
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Pharmacology
Autoimmune Experimental Encephalomyelitis
Brain Diseases
Genetic Polymorphisms
Atopic Dermatitis
Neurodegenerative Diseases
Multiple Sclerosis
Parkinson Disease
Disease Progression
Epilepsy
Rheumatoid Arthritis
Alzheimer Disease
Cardiovascular Diseases
Ischemia
Asthma
Animal Models
Inflammation
Lipids
cysteinyl-leukotriene
Brain

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases. / Gelosa, Paolo; Colazzo, Francesca; Tremoli, Elena; Sironi, Luigi; Castiglioni, Laura.

In: Mediators of Inflammation, Vol. 2017, 3454212, 01.01.2017.

Research output: Contribution to journalReview article

@article{8ade17ebf18f4ff0b4c8613c456c3bea,
title = "Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases",
abstract = "Cysteinyl leukotrienes (CysLTs) are potent lipid mediators widely known for their actions in asthma and in allergic rhinitis. Accumulating data highlights their involvement in a broader range of inflammation-associated diseases such as cancer, atopic dermatitis, rheumatoid arthritis, and cardiovascular diseases. The reported elevated levels of CysLTs in acute and chronic brain lesions, the association between the genetic polymorphisms in the LTs biosynthesis pathways and the risk of cerebral pathological events, and the evidence from animal models link also CysLTs and brain diseases. This review will give an overview of how far research has gone into the evaluation of the role of CysLTs in the most prevalent neurodegenerative disorders (ischemia, Alzheimer's and Parkinson's diseases, multiple sclerosis/experimental autoimmune encephalomyelitis, and epilepsy) in order to understand the underlying mechanism by which they might be central in the disease progression.",
author = "Paolo Gelosa and Francesca Colazzo and Elena Tremoli and Luigi Sironi and Laura Castiglioni",
year = "2017",
month = "1",
day = "1",
doi = "10.1155/2017/3454212",
language = "English",
volume = "2017",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases

AU - Gelosa, Paolo

AU - Colazzo, Francesca

AU - Tremoli, Elena

AU - Sironi, Luigi

AU - Castiglioni, Laura

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Cysteinyl leukotrienes (CysLTs) are potent lipid mediators widely known for their actions in asthma and in allergic rhinitis. Accumulating data highlights their involvement in a broader range of inflammation-associated diseases such as cancer, atopic dermatitis, rheumatoid arthritis, and cardiovascular diseases. The reported elevated levels of CysLTs in acute and chronic brain lesions, the association between the genetic polymorphisms in the LTs biosynthesis pathways and the risk of cerebral pathological events, and the evidence from animal models link also CysLTs and brain diseases. This review will give an overview of how far research has gone into the evaluation of the role of CysLTs in the most prevalent neurodegenerative disorders (ischemia, Alzheimer's and Parkinson's diseases, multiple sclerosis/experimental autoimmune encephalomyelitis, and epilepsy) in order to understand the underlying mechanism by which they might be central in the disease progression.

AB - Cysteinyl leukotrienes (CysLTs) are potent lipid mediators widely known for their actions in asthma and in allergic rhinitis. Accumulating data highlights their involvement in a broader range of inflammation-associated diseases such as cancer, atopic dermatitis, rheumatoid arthritis, and cardiovascular diseases. The reported elevated levels of CysLTs in acute and chronic brain lesions, the association between the genetic polymorphisms in the LTs biosynthesis pathways and the risk of cerebral pathological events, and the evidence from animal models link also CysLTs and brain diseases. This review will give an overview of how far research has gone into the evaluation of the role of CysLTs in the most prevalent neurodegenerative disorders (ischemia, Alzheimer's and Parkinson's diseases, multiple sclerosis/experimental autoimmune encephalomyelitis, and epilepsy) in order to understand the underlying mechanism by which they might be central in the disease progression.

UR - http://www.scopus.com/inward/record.url?scp=85020043153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020043153&partnerID=8YFLogxK

U2 - 10.1155/2017/3454212

DO - 10.1155/2017/3454212

M3 - Review article

AN - SCOPUS:85020043153

VL - 2017

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 3454212

ER -